References
- Lacroix BD, Friberg LE, Karlsson MO. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. J Pharmacokinet Pharmacodyn. 2012;39:177-193. https://doi.org/10.1007/s10928-012-9240-x
-
psn.sourceforge.net [Internet]. PsN: perl-speaks-NONMEM;
${\copyright}$ 2008 by Mats Karlsson, Niclas Jonsson and Andrew Hooker. [cited 2012 Feb 15]. Available from: http://psn.sourceforge.net. - Beal SL, Sheiner LB, Boeckmann AJ (Eds.). NONMEM Users Guides - Part VII. Ellicott City, Maryland, USA.: Icon Development Solutions; 1989-2006.
- Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007;34:575-593. https://doi.org/10.1007/s10928-007-9060-6
- Pawitan Y. In all likelihood: statistical modelling and inference using likelihood. New York: Oxford University Press.; 2001.
- D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User' s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 2009.
- Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558-569. https://doi.org/10.1208/s12248-009-9133-0
- Balram C, Lim BL, Lee EJ, Wong SY, Ang B. Validity of Bayesian forecasting programme in therapeutic drug monitoring of vancomycin in a surgical intensive care unit: a prospective evaluation. Ann Acad Med Singapore. 1996;25:492-495.
- el Desoky E, Meinshausen J, Buhl K, Engel G, Harings-Kaim A, Drewelow B, Klotz U. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit. 1993;15:281-288. https://doi.org/10.1097/00007691-199308000-00004
- Pons G, Treluyer JM, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit. 2002;24:9-14. https://doi.org/10.1097/00007691-200202000-00002
- Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20. https://doi.org/10.1038/sj.clpt.6100241
- Park K, Verotta D, Gupta SK, Sheiner LB. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J Pharmacokinet Biopharm. 1998;26:471-492. https://doi.org/10.1023/A:1021068202606
- Ette EI, Williams PJ. Pharmacometrics - The Science of Quantitative Pharmacology. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2007.
Cited by
- Inter occasion variability in individual optimal design vol.42, pp.6, 2012, https://doi.org/10.1007/s10928-015-9449-6
- R-based reproduction of the estimation process hidden behind NONMEM® Part 1: first-order approximation method vol.23, pp.1, 2012, https://doi.org/10.12793/tcp.2015.23.1.1
- R-based reproduction of the estimation process hidden behind NONMEM® Part 2: First-order conditional estimation vol.24, pp.4, 2012, https://doi.org/10.12793/tcp.2016.24.4.161
- Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs vol.103, pp.4, 2012, https://doi.org/10.1002/cpt.777
- Using a three-compartment model improves the estimation of iohexol clearance to assess glomerular filtration rate vol.8, pp.None, 2012, https://doi.org/10.1038/s41598-018-35989-x
- Application of Pharmacometrics in Pharmacotherapy: Open-Source Software for Vancomycin Therapeutic Drug Management vol.11, pp.5, 2012, https://doi.org/10.3390/pharmaceutics11050224
- Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data vol.12, pp.1, 2020, https://doi.org/10.1186/s13195-020-00630-5
- Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr vol.10, pp.10, 2012, https://doi.org/10.1002/psp4.12689